Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study

Fig. 1

Kaplan-Meier curves on 1-year overall survival in erlotinib-treated patients. a) Overall survival in the whole study population according to prespecified age group. b) Overall survival in patients with squamous carcinoma, patients with non-squamous EGFR wild-type carcinoma and patients with EGFR activating mutations. c) Overall survival according to age group (< 75 vs ≥75 years) in patients with squamous carcinoma and in patients with non-squamous EGFR wild-type carcinoma. CI, confidence interval; EGFR, epidermal growth factor receptor gene; HR, hazard ratio; NSCLC, non-small-cell lung cancer; OS, overall survival; WT, wild-type.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us